Bias, Blinding, and Why Double-Blind Phase III Matters

The short version

Bias is any systematic error that causes a trial to produce an estimate of treatment effect that is consistently different from the true effect. Blinding, allocation concealment, and intention-to-treat analysis are the main methodological tools that trials use to minimize bias. When a trial is described as "Phase III, randomized, double-blind, placebo-controlled," each of those words addresses a specific bias risk. Understanding which biases each element controls helps you decide how much weight to give any reported result.

The hierarchy of trial evidence

Evidence quality in clinical medicine is ranked by how well a study design controls for bias and confounding. From lowest to highest:

1. Case report / case series. Uncontrolled observations of outcomes in one or a few patients. Hypothesis-generating; no comparison group; cannot distinguish drug effect from natural disease course or coincidence.
2. Observational cohort study. A group of patients receiving a treatment is followed over time and compared with a group not receiving it. Selection into treatment is not randomized; confounding by indication is the central validity threat (sicker patients may be more likely to receive a drug, distorting the apparent treatment effect).
3. Non-blinded (open-label) randomized controlled trial (RCT).Participants are randomly assigned to treatment or control, eliminating selection confounding, but both participants and investigators know which treatment is received. Measurement bias and placebo effect can still operate.
4. Double-blind RCT. Both participants and outcome assessors are unaware of treatment assignment. This controls for placebo effect, observer bias, and differential care. The gold standard for efficacy evidence.
5. Meta-analysis of double-blind RCTs. Pooled analysis of multiple high-quality trials, providing more precise effect estimates and the ability to examine heterogeneity across populations and protocols.

For peptide metabolic drugs, most pivotal efficacy evidence comes from double-blind or double-dummy RCTs. Cardiovascular outcomes trials are typically open-label for the comparison between the study drug and placebo but use blinded endpoint adjudication (an independent committee classifies events without knowing treatment assignment).^[2]

Sources of bias in clinical trials

Selection bias

Occurs when the groups being compared are systematically different at baseline in ways that affect the outcome. In randomized trials, selection bias at enrollment is controlled by randomization, provided the allocation sequence is properly generated (e.g., by computer-generated random numbers) and concealed from the people assigning participants to treatment. Selection bias can re-enter through differential dropout (see attrition bias below) or through post-hoc subgroup analyses that identify "responders" after unblinding.

Measurement bias

Occurs when the outcome is measured differently across treatment groups. A trial where investigators know which treatment a patient is receiving may unconsciously probe for side effects more thoroughly in the active arm, inflating the apparent adverse-event rate. Conversely, unblinded investigators may be more generous in classifying ambiguous clinical events as drug-related benefits in the active arm.

Recall bias

Particularly relevant to patient-reported outcomes and retrospective adverse-event collection. Patients who experience a salient side effect may recall it more vividly and report it more completely than controls who experienced no drug effect. Systematic, scheduled adverse-event elicitation (as opposed to spontaneous reporting alone) mitigates recall bias by asking all patients the same questions at the same time points.

Attrition bias

Occurs when participants drop out of the trial in patterns related to treatment or outcome. If patients in the active arm who are not responding drop out at higher rates, the remaining active-arm participants appear to be doing well. Conversely, if active-arm patients who experience side effects drop out, the apparent tolerability of the drug is overestimated. Dropout rates and reasons for discontinuation must be reported and analyzed to assess the impact of attrition.^[3]

Reporting bias

Occurs when the decision to publish a study, or the choice of outcomes reported within a study, is influenced by the direction or magnitude of the results. Positive trials are more likely to be published than negative ones (publication bias). Within a trial, statistically significant secondary endpoints are more likely to be prominently reported than non-significant ones. ClinicalTrials.gov result posting requirements and trial registry outcome prespecification are the primary tools to detect and limit reporting bias; a registered primary endpoint that differs from the one analyzed in the publication is a red flag.

Blinding: what it means and how it is done

Blinding (also called masking) refers to keeping one or more parties in a trial unaware of treatment assignment. The relevant parties are: the participant, the treating clinician, the outcome assessor, and the data analyst.

• Single-blind. Only one party (usually the participant) is unaware of treatment assignment. The clinician knows which treatment was given, creating potential for differential care and measurement bias.
• Double-blind. Both the participant and the outcome assessors are unaware of treatment assignment. This controls for placebo effect, observer bias, and differential adverse-event elicitation. Most pivotal peptide efficacy trials are double-blind.^[1]
• Double-dummy design. Used when the active treatment and control cannot be made physically identical (e.g., one drug is a once-weekly injection and the comparator is a once-daily pill). Each participant receives two products: the assigned active drug plus a matching placebo for the comparator, or the assigned comparator plus a matching placebo for the active drug. This maintains blinding across formulation differences. The SURPASS-2 trial used a double-dummy design to blind participants and investigators to whether they were receiving tirzepatide or semaglutide.
• Sham injection. In trials comparing an injectable peptide against an oral control, participants in the oral arm may receive sham (inactive) subcutaneous injections to maintain participant blinding.

Blinding is not always fully successful. Participants may infer their treatment from side effects (nausea strongly suggests active GLP-1 agonist). Assessment of blinding integrity (e.g., asking participants to guess their treatment assignment) is rarely reported but informative. When blinding is compromised, the direction of bias depends on whether participants or investigators prefer the active or control condition.

Allocation concealment

Allocation concealment is not the same as blinding. Blinding refers to unawareness of treatment assignment during and after the trial. Allocation concealment refers to the process of keeping the randomization sequence hidden from the people enrolling participants, so that knowledge of which treatment the next participant will receive cannot influence the decision to enroll or exclude them.^[4]

Without proper allocation concealment, investigators could (consciously or not) enroll a healthier patient when they anticipate the next allocation will be active drug, biasing baseline characteristics toward the active arm. Adequate concealment methods include: central randomization via a telephone or web-based system, sequentially numbered opaque sealed envelopes, and pharmacy-controlled dispensing. Inadequate methods include open lists or alternating assignments that allow the next allocation to be predicted.

Trials with inadequate allocation concealment systematically overestimate treatment effects compared with adequately concealed trials; the magnitude of this bias is estimated at 30-40% in some meta-epidemiological analyses.^[3]

Intention-to-treat versus per-protocol analysis

Once participants are randomized, the question is: whose data are included in the final efficacy analysis?

• Intention-to-treat (ITT) analysis. All randomized participants are analyzed in the group to which they were assigned, regardless of whether they completed treatment, received the correct treatment, or adhered to the protocol. ITT preserves the protection against selection bias provided by randomization. If participants drop out and their missing outcomes are imputed (e.g., using multiple imputation or mixed-model repeated measures), the analysis is sometimes called a "modified ITT" or "full analysis set." ITT is the regulatory standard for efficacy analysis in confirmatory trials.^[5]
• Per-protocol (PP) analysis. Only participants who adequately adhered to the protocol (received the assigned treatment, completed the planned assessments, had no major protocol deviations) are analyzed. PP analysis estimates the effect of the drug under ideal adherence conditions (efficacy under best-case use). It is useful as a sensitivity analysis to accompany ITT but should not replace it as the primary analysis, because adherence is not random and selecting for adherent participants reintroduces selection bias.

A drug that shows a large PP effect but a modest ITT effect tells you that the drug works well in people who take it correctly, but that real-world use (with typical adherence) will produce smaller population-level benefits.

Evaluating industry-funded trials

The large majority of pivotal peptide metabolic trials are funded by the drug's sponsor. Systematic reviews find that industry-funded drug trials are approximately 2-4 times more likely to report results favourable to the sponsor's product than independently funded trials of the same products.^[6] This does not mean sponsor-funded trials are fabricated or fraudulent; it reflects a range of factors including publication bias, endpoint and comparator selection, and trial design choices.

Practical checklist for reading a sponsor-funded peptide trial:

1. Was the comparator chosen fairly? Comparing the new drug to a low dose of an established drug, or to a drug known to have suboptimal efficacy, can produce a favourable result that does not reflect the true competitive landscape. Check whether the comparator dose was within the approved or guideline-recommended range.
2. Does the registered primary endpoint match the published primary endpoint?Endpoint switching between trial registration and publication is a form of selective reporting. Cross-reference the ClinicalTrials.gov record with the published paper.^[7]
3. Were negative secondary endpoints reported with equal prominence as positive ones? Journals and sponsors have incentives to highlight positive findings. Check the supplementary tables for secondary endpoints that did not reach significance.
4. What was the dropout rate and how was missing data handled?High dropout rates or imputation methods that assume missing data are missing at random (when they are more likely to be missing because of adverse effects or lack of efficacy) can mask a drug's true performance.
5. Who had editorial control? Assess whether the paper acknowledges that the sponsor had a role in data collection, analysis, or manuscript review. Author agreements that deny the sponsor editorial override are more protective; professional medical writing funded by the sponsor without disclosure is a concern.

The Cochrane RoB 2 tool provides a structured framework for assessing risk of bias across five domains: randomization, deviations from intended interventions, missing outcome data, outcome measurement, and selection of reported results. Applying this framework to any trial you read will make the assessment systematic rather than impressionistic.^[7]